Studies on the outcome of lupus nephritis according to long-term treatment employing different modes of immunotherapy

The Japanese Journal of Nephrology

Volumn 34, Issue 9, 1992, Pages 1003-1009

  Hashimoto, Hiroshi ^a   Sugawara, Masahiro ^a   Tsuda, Hiroshi ^a   Kabasawa, Kazuyuki ^a   Hirose, Shunichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

immunosuppressants; lupus nephritis; outcome; plasmapheresis; pulse therapy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE;

ARTICLE; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; SURVIVAL;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; CHILD; COMPLEMENT 3; COMPLEMENT 4; FEMALE; HUMAN; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUPUS NEPHRITIS; MALE; MIDDLE AGE; PLASMAPHERESIS; PREDNISOLONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0026449012     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: 10.14842/jpnjnephrol1959.34.1003     Document Type: Article

References (22)

1. Kaplan D: Treatment of systemic lupus erythematosus. Arthritis Rheum 20: S175-S179, 1977
2. Hashimoto H., Shiokawa Y: Changing pattern in the clinical features and prognosis of systemic lupus erythematosus-a Japanese experience. J Rheumatol 9: 386-389, 1982
3. Wallace D.J., Dubois EL: Prognostic subsets, natural course and causes of death in systemic lupus erythematosus. In: Wallace DJ and Dubois E.L., eds. Dubois’ Lupus Erythematosus, 3rd Ed. Philadelphia, Lea & Febiger, 1987: 580-602
4. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., Me Shane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982
5. Arden L.A., DeGroot E.R., Feltkamp TEW: Immunology of DNA III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. An NY Acad Sci 254: 505-515, 1975
6. Marrel M., Shulman LE: Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chron Dis 1: 12-32, 1955
7. Austin H.A., Muenz L.R., Joyce K.M., Antonovych T.A., Kullick M.E., Klippe J.H., Decker J.L., Balow JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75: 382-391, 1983
8. Poliak V.E., Pirani C.L., Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 63: 537-550, 1964
9. Baldwin D.S., Lowenstein J., Rothfield N.F., Gallo G., Mccluskey RT: The clinical course of the proliferative and membranous form of lupus nephritis. Ann Intern Med 73: 929-942, 1970
10. Appel G.B., Cohen D.J., Pirani C.L., Meltzer J.I., Estes D: Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 83: 877-885, 1987
11. Poliak V.E., Pirani C.L., Kark RM: Effect of large doses of prednisolone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 51: 495-511, 1961
12. Rothfield N., Stollar BD: The relationship of immunoglobulin class pattern of antinuclear antibody and complement fixing antibodies to DNA in sera of patients with systemic lupus erythematosus. J Clin Invest 46: 1785-1794, 1967
13. Schur P.H., Monroe M., Rothfield N: The subclass of antinuclear and antinucleic acid antibodies. Arthritis Rheum 15: 174-182, 1972
14. Sontheimer R.D., Gilliam LN: DNA antibody class, subclass and complement fixation in systemic lupus erythematosus with and without nephritis. Clin Immunol Immunopathol 10: 459-467, 1978
15. Hashimoto H., Utagawa Y., Yamagata J., Okada T., Shiokawa Y., Suzuki S., Tomiyama T: The relationship of renal histopathological lesions to immunoglobulin classes and complement fixation of anti-native DNA antibodies in systemic lupus erythematosus. Scand J Rheum 12: 209-214, 1983
16. Kohno A., Yoshida H., Sekita K., Maruyama N., Ozaki S., Hirose S., Shirai T: Genetic regulation of the class conversion of dsDNA-specific antibodies in (NZB X NZW)F1 hybrid. Immunogenetics 18: 513-524, 1983
17. Hirose G., Ueda G., Noguchi K., Okada T., Sekigawa I., Sato H., Shirai T: Requirement of H-2 heterozygosity for autoimmunity in (NZB X NZW)F1 hybrid mice. Eur J Immunol 16: 1631-1633, 1986
18. Shirai T., Hirose S., Sekigawa I., Okada T., Sato H: Geneic and cellular basis of anti-DNA antibody synthesis in systemic lupus erythematosus of New Zealand mice. J Rheumatol (suppl 13) 14: 11-20, 1987
19. Kimberly R.P., Lockshin M.D., Sherman R.L., McDougal J.S., Inman R.D., Christian CL: High dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70: 817-824, 1981
20. Jones J.V.: Plasmapheresis in SLE. Clin Rheum Dis 8: 243-260, 1982
21. Donadio JV Jr, Holley K.E., Ilstrup DM: Cytotoxic drug treatment of lupus nephritis. Am J Kidney Dis 2: 82-88, 1982
22. Steinberg A.D., Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone only. Arthritis Rheum 34: 945-950, 1991